Equities

Fibrobiologics Inc

Fibrobiologics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.58
  • Today's Change-0.17 / -6.18%
  • Shares traded16.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 09 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FibroBiologics Inc is a United States-based company. The Company operates as a biopharmaceutical company. It is focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. It also develops biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.

  • Revenue in USD (TTM)0.00
  • Net income in USD-19.47m
  • Incorporated2021
  • Employees10.00
  • Location
    Fibrobiologics Inc455 E. Medical Center Blvd, Suite 300HOUSTON 77598United StatesUSA
  • Phone+1 (281) 671-5150
  • Fax+1 (302) 655-5049
  • Websitehttps://fibrobiologics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ALX Oncology Holdings Inc0.00-171.44m85.33m74.00--0.5334-----3.64-3.640.003.040.00----0.00-74.45-34.34-84.76-36.47-------7,238.76----0.0734-------30.23--14.30--
Hillevax Inc0.00-156.27m86.13m90.00--0.4161-----3.38-3.380.004.160.00----0.00-55.47---63.02--------------0.1113------22.68------
Avalo Therapeutics Inc807.00k-36.22m87.43m19.00------108.34-63.82-63.820.3347-2.080.0122--20.9642,473.68-54.66-99.64-529.15-154.4264.1984.69-4,488.60-613.58---------89.34-22.8324.28---22.48--
X4 Pharmaceuticals Inc563.00k17.63m89.47m93.006.200.94564.96158.920.08570.08570.00280.56160.0029--0.67266,053.769.18-61.5310.59-69.2052.40--3,131.79-13,288.936.04--0.4427-------4.93--12.03--
CytomX Therapeutics Inc119.57m11.09m89.84m120.008.39--6.920.75130.13710.13711.45-0.39970.6491--51.12996,408.306.02-21.5326.34-32.32----9.27-100.38--------90.3811.2199.43---26.01--
Leap Therapeutics Inc0.00-60.34m90.30m54.00--1.37-----2.00-2.000.001.720.00----0.00-67.81-80.06-80.19-95.03-------7,900.37----0.00-------49.12------
Genelux Corp8.00k-26.54m90.48m23.00--2.37--11,310.37-0.9704-0.97040.00031.110.0002----347.83-69.34---84.43-------331,725.00------0.00---98.46---443.44------
Fibrobiologics Inc0.00-19.47m90.71m10.00---------0.939-0.9390.00-0.0730.00----0.00-171.13---333.35-----------------------272.15------
Ikena Oncology Inc1.84m-66.71m93.41m18.00--0.5776--50.66-1.43-1.430.03932.960.0112----42,883.72-40.52-29.72-43.17-34.62-----3,617.57-294.90----0.00---41.3556.050.8711--6.30--
Allovir Inc0.00-140.34m93.49m112.00--0.7769-----1.23-1.230.001.040.00----0.00-67.85-52.85-73.72-57.72-------378,613.90----0.00-------12.87------
MDxHealth SA80.74m-40.80m95.05m300.00------1.18-1.54-1.543.06-0.32290.59069.397.49269,136.70-29.85-51.62-43.63-64.7262.6450.88-50.54-117.640.8252-1.741.18--89.4319.842.14--30.13--
Medicinova Inc1.00m-8.16m95.64m13.00--1.67--95.64-0.1665-0.16650.02041.170.0155----76,923.08-12.65-15.36-13.19-15.90-----816.49-1,182.54----0.00------39.08--15.87--
bluebird bio Inc54.90m-311.44m95.89m375.00--1.81--1.75-2.19-2.190.35740.27330.09093.21--146,400.00-51.54-34.75-80.31-40.84-37.34-124.35-567.29-5,770.410.5712-19.810.7827--720.04-11.588.00---30.47--
Bioatla Inc0.00-104.56m96.67m65.00--3.08-----2.18-2.180.000.64910.00----0.00-84.23-48.72-106.06-57.35-------6,651.71----0.00-------15.95---37.01--
Data as of Oct 09 2024. Currency figures normalised to Fibrobiologics Inc's reporting currency: US Dollar USD

Institutional shareholders

7.31%Per cent of shares held by top holders
HolderShares% Held
Fund Evaluation Group LLCas of 30 Jun 20241.06m3.23%
Geode Capital Management LLCas of 30 Jun 2024315.71k0.97%
Cascade Financial Partners LLCas of 30 Jun 2024315.06k0.96%
Millennium Management LLCas of 31 Mar 2024209.23k0.64%
Transform Wealth LLCas of 30 Jun 2024133.89k0.41%
Requisite Capital Management LLCas of 30 Jun 2024109.71k0.34%
American Institute for Advanced Investment Management LLPas of 30 Jun 202488.21k0.27%
HRT Financial LLCas of 31 Mar 202457.34k0.18%
The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 202456.08k0.17%
Marshall Wace LLPas of 31 Mar 202452.03k0.16%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.